ReviewJournal of Parkinson's disease2018
Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease.
Review in Journal of Parkinson's disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.Journal of Parkinson's disease · 2021Pooled it
- Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related complications: a phase 1/2 randomized-controlled trial.Nature medicine · 2025Trial
- Neuropsychiatric and Cognitive Safety of Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Insights From a Real-World Cohort.Journal of movement disorders · 2026Article
- Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach.Current diabetes reviews · 2025Review
- Analysis of key lncRNA related to Parkinson's disease based on gene co-expression weight networks.Neurosciences (Riyadh, Saudi Arabia) · 2025Article
- Therapeutic drug monitoring in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Misfolding and aggregation in neurodegenerative diseases: protein quality control machinery as potential therapeutic clearance pathways.Cell communication and signaling : CCS · 2024Review
- A Comprehensive Approach to Parkinson's Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects.International journal of molecular sciences · 2024Review
- Accessibility of Device-Aided Therapies for Persons With Parkinson's Disease in Poland.Journal of movement disorders · 2024Article
- Can Continuous Levodopa Delivery Be Achieved in the Absence of Intrajejunal Levodopa Infusion? Implications for India and Underserved Countries.Movement disorders clinical practice · 2024Article
- Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS.Journal of neurology · 2023Observational
- Intermittent Apomorphine Use for off Period Rescue in Parkinson's Disease: A Pragmatic Review of over Three Decades of Clinical Experience.Movement disorders clinical practice · 2023Review
- Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson's disease: Post-hoc analyses from a large 54-week trial.Clinical parkinsonism & related disorders · 2023Article
- The risk of developing motor complications with Levodopa immediate versus dual release upon treatment initiation in Parkinson's disease.Clinical parkinsonism & related disorders · 2023Article
- Advances in the Pharmacological and Non-pharmacological Management of Non-motor Symptoms in Parkinson's Disease: An Update Since 2017.Current neuropharmacology · 2023Review
- Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?Translational neurodegeneration · 2022Review
- Designing nanocarriers to overcome the limitations in conventional drug administration for Parkinson's disease.Neural regeneration research · 2022Article
- Continuous dopaminergic stimulation counteracts L-DOPA-induced overactivity of CaExperimental brain research · 2022Article
- Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Continuous dopaminergic stimulation in Parkinson's disease (PD) has several advantages over pulsatile, non-continuous, stimulation. These therapies currently consist of pump-based and transcutaneous therapies and are based on a more constant delivery of the dopaminergic drug resulting in continuous dopaminergic stimulation and a more stable treatment effect. Several clinical and experimental observations have shown that continuous stimulation of dopaminergic receptors induces fewer complications, such as dyskinesia, compared to pulsatile stimulation. Currently available non-oral pharmacological continuous therapies in PD include the transdermal Rotigotine (RTG) patch, infusion therapies with Apomorphine and Intrajejunal Levodopa (IJLI) and the Rivastigmine patch. Here we aim to provide a concise review of these current therapies and discuss ongoing and future developments of continuous non-oral pharmacological dopaminergic therapies in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.